Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Yimin Mao, Shiwu Ma, Chenghai Liu, Xiaoyan Liu, Minghua Su, Dongliang Li, Yiling Li, Gongying Chen, Jun Chen, Jinjun Chen, Jingmin Zhao, Xiaoyan Guo, Jie Tang, Yuzheng Zhuge, Qing Xie, Wen Xie, Rongtao Lai, Dachuan Cai, Qingxian Cai, Yang Zhi, Xiaoyun Li
Abstract
Drug-induced liver injury (DILI) is an important adverse drug reaction that can lead to acute liver failure or even death in severe cases. Currently, the diagnosis of DILI still follows the strategy of exclusion. Therefore, a detailed history taking and a thorough and careful exclusion of other potential causes of liver injury is the key to correct diagnosis. This guideline was developed based on evidence-based medicine provided by the latest research advances and aims to provide professional guidance to clinicians on how to identify suspected DILI timely and standardize the diagnosis and management in clinical practice. Based on the clinical settings in China, the guideline also specifically focused on DILI in chronic liver disease, drug-induced viral hepatitis reactivation, common causing agents of DILI (herbal and dietary supplements, anti-tuberculosis drugs, and antineoplastic drugs), and signal of DILI in clinical trials and its assessment.